Form 4: Daewoong Pharmaceutical Invests $5 Million in AEON Biopharma via Convertible Note

Daewoong Pharmaceutical acquires a $5 million senior secured convertible note in AEON Biopharma, potentially converting into common stock upon a qualified financing event.

Summary

• Daewoong Pharmaceutical Co., Ltd. (DWP) has invested $5 million in AEON Biopharma, Inc. through a senior secured convertible note.
• The convertible note accrues interest at an annual rate of 15.79% and matures three years from the funding date (March 24, 2024).
• The note is convertible into shares of AEON Biopharma's Class A common stock under certain conditions.
• If AEON Biopharma completes a qualified financing of at least $30 million, the note will automatically convert into common stock.
• The conversion rate is determined by a formula involving the principal amount, accrued interest, and the per-share price of common stock in the qualified financing, provided the per-share price is at least $1.00.
• Daewoong Co., Ltd. indirectly owns the shares through its 52% ownership of Daewoong Pharmaceutical Co., Ltd.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The investment from Daewoong Pharmaceutical is a positive sign for AEON Biopharma, but the high interest rate and dependence on a future qualified financing introduce some uncertainty.

Positives

• AEON Biopharma receives a $5 million investment from Daewoong Pharmaceutical.
• The convertible note structure allows for potential equity upside for Daewoong Pharmaceutical if AEON Biopharma performs well.
• The 15.79% interest rate provides a steady return for Daewoong Pharmaceutical.
• Automatic conversion upon a qualified financing event simplifies the conversion process.

Negatives

• The high interest rate of 15.79% on the convertible note could be a burden for AEON Biopharma.
• The conversion is contingent on AEON Biopharma achieving a qualified financing of at least $30 million.
• The exact number of shares to be received upon conversion is indeterminate due to the terms and conditions of the note.

Risks

• AEON Biopharma may not be able to secure a qualified financing of at least $30 million, preventing the automatic conversion.
• The value of AEON Biopharma's common stock could decline, reducing the potential return on the convertible note.
• The terms of the convertible note contain customary events of default, which could trigger early repayment or other adverse consequences.
• Changes in market conditions or regulatory requirements could impact the value or convertibility of the note.

Future Outlook

The future outlook depends on AEON Biopharma's ability to secure a qualified financing of at least $30 million, which would trigger the automatic conversion of the note into common stock. The value of the investment is tied to the performance of AEON Biopharma and the market price of its common stock.

Industry Context

Convertible notes are a common financing tool for biotech companies, allowing investors to participate in potential upside while providing debt financing. The high interest rate reflects the risk associated with investing in a company like AEON Biopharma. Daewoong Pharmaceutical's investment signals confidence in AEON Biopharma's prospects.

Comparison to Industry Standards

• Convertible notes are frequently used in the biopharmaceutical industry to fund research and development or clinical trials.
• The 15.79% interest rate is relatively high, suggesting a higher risk profile compared to more established companies.
• Similar deals often include conversion features tied to milestones or financing events.
• Comparable companies might include other early-stage biotech firms that have raised capital through convertible notes or private placements.

Stakeholder Impact

• Shareholders of AEON Biopharma may see dilution if the convertible note is converted into common stock.
• Employees of AEON Biopharma may benefit from the additional funding, which could support research and development efforts.
• Customers and suppliers of AEON Biopharma may see improved stability and growth potential due to the investment.
• Creditors of AEON Biopharma may be impacted by the terms of the convertible note, which could affect the company's financial obligations.

Next Steps

• AEON Biopharma needs to secure a qualified financing of at least $30 million to trigger the automatic conversion of the note.
• Daewoong Pharmaceutical will monitor AEON Biopharma's progress and the market conditions to assess the value of its investment.
• Both companies will need to comply with the terms and conditions of the subscription agreement and the convertible note.

Key Dates

Keywords

convertible note, AEON Biopharma, Daewoong Pharmaceutical, qualified financing, investment, common stock